ASH 2022 | Highlights in AL amyloidosis from ASH 2022: EMN22, EMN27 & predictors of hematologic CR
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, shares the most important updates in light chain (AL) amyloidosis from ASH 2022, commenting on the EMN22 study (NCT04131309) evaluating daratumumab monotherapy in patients with newly diagnosed stage IIIb AL amyloidosis, the EMN27 study (NCT04617925) evaluating belantamab mafodotin in relapsed/refractory (R/R) amyloidosis, and a study investigating predictive factors for hematologic complete response (CR) in patients treated with non-transplant-based regimens. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena: Consultancy; Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion, Pfizer, Janssen, Attralus, Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena: Consultancy, Research Funding, Speakers Bureau.
